Dr Reddy’s Laboratories Q3 report: Net profit of Rs 20 crore

Revenue for the quarter stood at Rs 4,930 crore which had increased by 12% YoY and 1% QoQ. The gross margin was 53.8% against 54.1% YoY and 53.9% QoQ. Selling, general and administrative (SG&A) expenses advanced 14% YoY and 10% QoQ to Rs 1,439 crore. Research and development expenses were Rs 411 crore for the quarter.

Earnings before interest, taxes, depreciation and amortization (EBITDA) was at Rs 1,185 crore and EBITDA margin stood 24% for Q3FY21.

The company’s Co-chairman & MD, G V Prasad stated, “We continued with our growth momentum while maintaining EBITDA margins. The profits were impacted due to trigger based impairment charge taken on a few acquired products including Nuvaring.”

“We are progressing well on phase 3 clinical trials for Sputnik V vaccine in India. We continue to focus on enhancing our product offerings to our patients to serve them better,” he added.

In the geographical segments, Europe and India were in the lead, rising 34% and 26% YoY, respectively.

North America observed growth of 9% YoY. On the other hand, emerging markets advanced by 5% YoY during the December quarter.